How do you know if a drug will actually work? The Leiden-based spin-off Omivera is developing a new technology that could provide clearer answers. The young company received a seed investment from the investment fund UNIIQ to support its development.

Leiden researchers, led by Sebastian Pomplun developed a new method to screen hundreds of thousands of molecules for drug discovery, using mass spectrometry instead of DNA tags. ‘We wanted to make drug discovery faster and more accessible.’

Immediately connect with the needs of industry with your master’s degree. The new course Practical Aspects of Quality Management in Pharma and Biotech provides just that. The LACDR and LUMC set up the course together with the Biotech Training Facility, located at the Leiden Bio Science Park. The first…

The AtheroNeth consortium received €6 million from the Dutch Heart Foundation to gain a better understanding of the differences in disease progression among patients with atherosclerosis. The ultimate goal is to enable personalised treatment.

How can you ensure that more experimental drugs reach the finish line? At the moment, only one in twenty cancer drugs that are tested on humans makes it to the market. This is an enormous loss for patients and society. With a grant from the National Growth Fund, Oncode-PACT aims to efficiently select…

For her bachelor’s thesis, Molecular Science and Technology student Madouc Bergers synthesized her own molecule that can inhibit the breakdown of sugars. Although most students do not even manage to make one building block, Madouc made three. Partly because of this, she has been nominated for the Science…

A new class of polymers has been used in patients for the first time. The compound is the first new drug solubilising agent in decades. Introduced in 2014 by chemist Matthias Barz from Leiden University, it offers a unique alternative to current options.